OSUROrasure Technologies, Inc.
Orasure Technologies, Inc. (OSUR) sells diagnostic tests and sample management solutions for point-of-need and home healthcare applications. The next catalyst is Nov 4, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to deliver on its growth narrative and stabilize its bottom line.
- Revenue fell 38.1% YoY to $116.89M, with a net loss of $52.22M and free cash flow of -$117.58M in the latest reporting period.
- The company has a low debt-to-equity ratio of 0.02x but faces steep negative margins (-44.7% TTM).
- Shareholders’ equity stands at $340.83M, but the path to profitability remains unclear.
The Read
OraSure’s stock has historically declined about 7% after meeting EPS estimates amid activist pressure but surged up to 25% when investor optimism grew around the activist push and the Sherlock platform launch.
The schedule
- Wed4Nov
The earnings release will test whether the company can deliver consistent revenue and margin improvements, following a recent earnings miss that pressured the stock. The focus will be on guidance and operational efficiency, not just the top-line.
- Thu19Nov
The investor day will provide clarity on strategic priorities and long-term growth plans, which could influence investor sentiment and valuation. This event is less impactful than earnings but still relevant for market positioning.
- Sun10Jan
The FDA update will test whether the company can secure regulatory approval for its key product, which is critical for revenue growth. The outcome will directly impact the stock's valuation and market perception.
- Sun14Feb
The earnings release will test whether the company can deliver improved financial results and guidance, following a recent earnings miss. The focus will be on revenue growth and margin expansion.
- Wed17Mar
The potential sale pressure from Altai Capital could test the stock's resilience against short-term speculation. The outcome will depend on whether the company can defend its valuation or negotiate a deal.
- Fri7May
The earnings release will test whether the company can sustain revenue growth and improve margins, following a recent earnings miss. The focus will be on guidance and operational efficiency.
- Thu5Aug
The return to prior levels may test whether the stock can sustain momentum or face further selling pressure. This event is less impactful than earnings but still relevant for market positioning.
- Fri6Aug
The earnings release will test whether the company can deliver improved financial results and guidance, following a recent earnings miss. The focus will be on revenue growth and margin expansion.
Past
- Fri11Sep
Actual outcome: Bull · $3.95 at outcome
OSUR's stock surged following a positive clinical trial readout, indicating promising results that could accelerate regulatory approval and expand market potential. The data likely demonstrated improved efficacy or safety profiles, enhancing investor sentiment and valuation expectations. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +21.2% from 2026-09-11 to 2026-09-28 (~2.2σ vs typical 10d vol). Target date 2026-09-20 reached; move through 2026-09-28 observed. Confidence 95%.
OSUR's stock surged following a positive clinical trial readout, indicating promising results that could accelerate regulatory approval and expand market potential. The data likely demonstrated improved efficacy or safety profiles, enhancing investor sentiment and valuation expectations. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +21.2% from 2026-09-11 to 2026-09-28 (~2.2σ vs typical 10d vol). Target date 2026-09-20 reached; move through 2026-09-28 observed. Confidence 95%.
- Fri7Aug
Actual outcome: Bear · $3.84 at outcome
OraSure Technologies reported Q2 2026 revenue of $30.6 million, exceeding guidance and rising 9.7% sequentially, with EPS at 0.09, matching estimates. The stock fell 7.4% post-earnings, likely due to mixed sentiment around the initial Sherlock platform launch performance and broader market concerns about growth sustainability.
First earnings report capturing the initial weeks of the Sherlock platform launch.
- Mon1Jun
Actual outcome: Bull · $3.97 at outcome
OraSure successfully executed the commercial launch of its CRISPR-based Sherlock Molecular OTC Self-Test across retail and clinical channels. The market reacted positively to the official rollout and the realization of the Sherlock Biosciences partnership, driving the stock to $4.24 and exceeding the bull target.
Official retail and clinical roll-out of the CRISPR-based molecular diagnostic tool in partnership with Sherlock Biosciences.
- Fri8May
Actual outcome: Mixed · $3.00 at outcome
OraSure reported Q1 2026 earnings with an EPS of -$0.27, exactly matching analyst estimates. Although the stock's initial reaction was relatively flat, shares subsequently rallied to exceed the $3.40 bull target over the following weeks. The in-line results and anticipated progress on the Sherlock platform launch helped stabilize market sentiment, driving a longer-term bullish reversal after a period of heavy revenue declines.
First quarter results following a year of heavy revenue decline; focus on guidance regarding the Sherlock platform launch.
- Mon9Mar
Actual outcome: Bear · $2.98 at outcome
OraSure reported Q4 EPS of -$0.27, meeting analyst estimates, but the stock declined 6.9% over the outcome period. The company's continued underperformance prompted activist investor Altai Capital Management to publicly push for a sale and board representation, though OraSure's management rejected the proposals while defending its own transformation strategy.
The final major earnings release reflecting the COVID-19 revenue tail-off. Market focus will be entirely on 2026 guidance, specifically the projected rate of core revenue growth for Diagnostics and Sample Management Solutions (SMS) and the timeline for achieving adjusted profitability. Management has guided to a return to growth in 2026.
Scouting Reports
Hormuz Closure Ignites E&P Supercycle as Fed Wrestles with Stagflation Risk
Mar 31, 2026
The massive supply shock emanating from the March 2026 US-Iran conflict has fundamentally rewired market leadership. With the Strait of Hormuz effectively closed—trapping roughly 20% of global oil tra
Read more →
As the Strait of Hormuz Closes, Defense Tech Becomes Wall Street's Premier Safe Haven
Mar 17, 2026
It is March 17, 2026, and the global economy is staring down one of the most significant supply chain disruptions in modern history. With the Strait of Hormuz closed amid a rapidly escalating U.S.-Ira
Read more →